Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
Protagonist Therapeutics (Nasdaq: PTGX) announced participation in a fireside chat at the Jefferies Next Generation IBD Therapeutics Summit, scheduled for October 19, 2021. Dinesh V. Patel, Ph.D. and Scott Plevy, M.D. will present, with the session available on-demand from 10:45 a.m. EST. Protagonist is advancing multiple peptide-based therapies, including rusfertide (PTG-300) for conditions like polycythemia vera and hereditary hemochromatosis, and a candidate for ulcerative colitis (PN-943). The company operates from Newark, California.
- None.
- None.
NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.
Presentation details:
Date: Tuesday, October 19, 2021
Time: Available on-demand starting at 10:45 a.m. EST
A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.
The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds included in this agreement are PTG-200, PN-235 and PN-232. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are currently in Phase 1 studies.
Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-jefferies-next-generation-ibd-therapeutics-summit-301397480.html
SOURCE Protagonist Therapeutics, Inc.
FAQ
When is Protagonist Therapeutics' presentation at the Jefferies Summit?
Who will participate in the Protagonist Therapeutics fireside chat?
What time will the Protagonist Therapeutics presentation be available?
What is rusfertide (PTG-300) used for?
What company ticker symbol is associated with Protagonist Therapeutics?
